<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01327976</url>
  </required_header>
  <id_info>
    <org_study_id>IDE G070025</org_study_id>
    <nct_id>NCT01327976</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of vBloc Therapy Delivered by the Maestro Rechargeable System for the Treatment of Obesity</brief_title>
  <acronym>ReCharge</acronym>
  <official_title>A Randomized, Double Blind Sham Controlled Clinical Trial to Evaluate the Safety and Efficacy of vBloc Therapy Delivered by the Maestro Rechargeable System for the Treatment of Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EnteroMedics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EnteroMedics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluated the safety and efficacy of the vBloc Therapy delivered by the Maestro
      Rechargeable System compared to a sham control for the treatment obesity. The Maestro
      Rechargeable System delivers intermittent, electrical blocking signals to the anterior and
      posterior trunks of the intra-abdominal vagus nerve (termed vBloc Therapy) and is designed to
      reduce sensations of hunger and produce satiety leading to weight loss. After approval from
      the institutional review board, subjects provided written consent and were randomized in a 2
      to 1 allocation to vBloc group (with laparoscopic placement of the leads and neuroregulator)
      or the sham group (placement of a custom sham neuroregulator only) on double-blinded basis.
      Both groups received similar diet and exercise counseling. Weight, adverse events, clinical
      laboratories, ECGs, eating questionnaires and quality of life data were evaluated throughout
      the 12 month study duration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Maestro® Rechargeable System is a neuromodulation system.

      All subjects will be randomized in a 2:1 allocation to vBloc or Sham.

      All subjects will be followed through the 12-month follow-up visit. Subjects in the Sham
      group who choose to have an active device will undergo a second surgery to receive the active
      device after study unblinding.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Experiencing Implant/Revision Procedure, Device or Therapy Related Serious Adverse Events (SAEs).</measure>
    <time_frame>12 months</time_frame>
    <description>To demonstrate that the implant/revision procedure, device and therapy related serious adverse event rate in the vBloc group at 12 months post-implant is significantly lower than 15%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Excess Weight Loss (EWL) by Body Mass Index (BMI) Method.</measure>
    <time_frame>12 months</time_frame>
    <description>Observe at least a 10% greater excess body weight loss (EWL) from randomization with the Maestro System after 12 months of vBloc Therapy compared to Sham by body mass index (BMI) method. (Body mass index is calculated by dividing body weight (kg) by body height (m) squared (BMI=kg/m2)).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Responder Rate in the Treatment Arm.</measure>
    <time_frame>12 months</time_frame>
    <description>The second co-primary effectiveness endpoint was based on responder rates with the following two requirements: (i) at least 55% of vBloc subjects would achieve a %EWL of at least 20%; and (ii) at least 45% of vBloc subjects would achieve a %EWL of at least 25%.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">239</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>vBloc (Active Device)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The treatment group will receive a functional device that will deliver charge to the vagus nerve during the study period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham (Non-active Device)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The control group will receive a functional, but non-active device that will deliver no charge to the vagus nerve during the study period</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>vBloc (Active Device)</intervention_name>
    <description>Active device will deliver vBloc Therapy</description>
    <arm_group_label>vBloc (Active Device)</arm_group_label>
    <other_name>Maestro® Rechargeable System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham (Non-active Device)</intervention_name>
    <description>Functional non-active control device will deliver no vBloc Therapy</description>
    <arm_group_label>Sham (Non-active Device)</arm_group_label>
    <other_name>Maestro® Rechargeable System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Signed informed consent

          2. Body mass index (BMI) ≥ 40 kg/m2 to 45 kg/m2 or BMI ≥ 35 kg/m2 to 39.9 kg/m2 with one
             or more obesity related co-morbid conditions. Co-morbid conditions may include one or
             more of the following:

               -  Type 2 diabetes mellitus as defined in inclusion criteria #5 (limited to 10% of
                  randomized subjects)

               -  Hypertension as defined by systolic pressure ≥140 mmHg and/or diastolic pressure
                  ≥90 mmHg a) treated or untreated with systolic ≥140 mmHg or diastolic ≥90 mmHg or
                  b) treated with systolic &lt;140 mmHg and diastolic &lt;90 mmHg

               -  Dyslipidemia as defined by total cholesterol ≥200 or LDL ≥130 a) treated or
                  untreated with total cholesterol ≥200 or LDL ≥130 or b) treated with total
                  cholesterol &lt;200 or LDL &lt;130

               -  Sleep apnea syndrome (confirmed by overnight p02 studies)

               -  Obesity-related cardiomyopathy

          3. Females or males Note: females of child-bearing potential must have a negative urine
             pregnancy test at Screen and also within 14 days of implant procedure followed by
             physician-approved contraceptive regimen for the duration of the study period.

          4. 18-65 years of age inclusive.

          5. Type 2 diabetes mellitus subjects:

               -  Glycosylated hemoglobin (HbA1c) 7.0 - 10.0 % inclusive at screening visit.
                  (Undiagnosed subjects that are found to have a HbA1c value between 7-10% at
                  screening must see their primary physician for diagnosis and medical treatment
                  before continuing in trial)

               -  Onset: 12 years or less since initial diagnosis.

               -  Currently not using insulin therapy, GLP-1 (glucagon-like peptide-1) receptor
                  agonists (e.g., exenatide, liraglutide) for diabetes treatment and have not been
                  on these treatments in the past 6 months.

               -  Creatinine within normal reference range.

               -  No history of proliferative retinopathy.

               -  No history of peripheral neuropathy.

               -  No history of autonomic neuropathy.

               -  No history of coronary artery disease, with or without angina pectoris.

               -  No history of peripheral vascular disease.

          6. Failure to respond to supervised diet/exercise program(s) in which the subject was
             engaged within the last five years.

          7. Ability to complete all study visits and procedures.

        Exclusion criteria

          1. Concurrent chronic pancreatic disease.

          2. History of Crohn's disease and/or ulcerative colitis.

          3. History of bariatric surgery, fundoplication, gastric resection or major
             upper-abdominal surgery (acceptable surgeries include cholecystectomy, hysterectomy).

          4. History of pulmonary embolism or blood coagulation disorders.

          5. Clinically significant hiatal hernias (&gt; 5 cm) known from subject's medical record or
             determined by barium swallow (upper GI x-ray) or upper endoscopy per PI discretion
             prior to implant.

          6. Current cirrhosis, portal hypertension and/or esophageal varices.

          7. Intra-operative exclusion: hiatal hernia requiring surgical repair or extensive
             dissection at esophagogastric junction at time of surgery.

          8. Treatment with prescription weight-loss drug therapy within the prior three months and
             the use of prescription drug therapy or the use of over-the-counter weight loss
             preparations for the duration of the trial.

          9. Smoking cessation within the prior six months.

         10. Known genetic cause of obesity (e.g., Prader-Willi Syndrome).

         11. Weight loss of more than 10% of body weight in the previous 12 months.

         12. Physician-prescribed diet with intent to lose weight prior to surgery (note:

             study subject may continue any personal eating plan they were on prior to study
             enrollment [see exclusion criterion #24]

         13. Current type 1 diabetes mellitus (DM).

         14. Current or recent history (within 12 months) of ongoing bulimia.

         15. Current alterations in treatment for thyroid disorders (stable treatment regimen for
             prior three months acceptable).

         16. Current alterations in treatment for epilepsy (stable treatment regimen for prior six
             months acceptable).

         17. Current treatment for peptic ulcer disease (previous history acceptable).

         18. Chronic (more than 4 weeks of daily use) treatment with narcotic analgesic drug
             regimens (treatment with non-steroidal anti-inflammatory drugs acceptable).

         19. Current alterations in treatment regimens of anti-cholinergic drugs, including
             tricyclic antidepressants (stable treatment regimen for prior six months acceptable).

         20. Current medical condition that, in the opinion of the investigator, would make subject
             unfit for surgery under general anesthesia or that would be exacerbated by intentional
             weight loss. Some examples include diagnosis of cancer, recent heart attack, recent
             stroke, or recent serious trauma.

         21. Presence of permanently implanted electrical powered medical device or implanted
             gastrointestinal device or prosthesis (e.g., pacemakers, implanted defibrillators,
             neurostimulators etc.).

         22. Planned or contemplated use of Magnetic Resonance Imaging (MRI) or oncologic radiation
             during the course of the trial.

         23. Psychiatric disorders (including untreated severe depression, schizophrenia, substance
             abuse, bulimia nervosa, etc.) or limited intellectual functioning which would
             potentially compromise the participant's ability to fully comprehend and/or cooperate
             with the study protocol. Psychiatric disorders will be established by a review of
             subject's medical history. For depression, a BDI (Beck Depression Inventory) score ≥
             29 will be considered to indicate severe depression.

         24. Current, active member of an organized weight loss program (e.g., Weight Watchers,
             TOPS).

         25. Current participant in another weight loss study or other clinical trials.

         26. Have a friend or family member who is currently participating or is planning to
             participate in this clinical trial.

         27. Patient reported:

               -  inability to walk for about 10 minutes without stopping,

               -  feeling of pain in chest when doing physical activity,

               -  feeling of pain in chest when not doing physical activity. Note: unless pain in
                  chest in known to be related to upper gastrointestinal disorders such as
                  gastroesophageal reflux disease or heartburn.

         28. Clinically significant cardiac rhythm disorder that requires either medical and/or
             surgical intervention (e.g., paroxysmal or chronic atrial fibrillation).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Sarr, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Billington, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HonorHealth (formerly Scottsdale Healthcare Bariatric Center)</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic Nutrition &amp; Metabolic Research Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Weight Control</name>
      <address>
        <city>Baulkham Hills</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adelaide Bariatric Centre</name>
      <address>
        <city>Bedford Park, SA</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2011</study_first_submitted>
  <study_first_submitted_qc>April 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2011</study_first_posted>
  <results_first_submitted>March 3, 2016</results_first_submitted>
  <results_first_submitted_qc>April 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 27, 2016</results_first_posted>
  <last_update_submitted>August 1, 2017</last_update_submitted>
  <last_update_submitted_qc>August 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Bariatric surgery</keyword>
  <keyword>Excess weight loss</keyword>
  <keyword>Vagus nerve</keyword>
  <keyword>Vagal blocking</keyword>
  <keyword>vBloc Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>vBloc (Active Device)</title>
          <description>The treatment group will receive a functional device that will deliver charge to the vagus nerve during the study period.
Active, implantable, intra abdominal vagal blocking medical device (Maestro® Rechargeable System): Active device will deliver vBloc Therapy.</description>
        </group>
        <group group_id="P2">
          <title>Sham (Non-active Device)</title>
          <description>The control group will receive a functional, but non-active device that will deliver no charge to the vagus nerve during the study period.
Active, implantable, intra abdominal vagal blocking medical device (Maestro® Rechargeable System): Control device will deliver no vBloc Therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>vBloc (Active Device)</title>
          <description>The vBloc group will receive a functional device that will deliver charge to the vagus nerve during the study period.
Active, implantable, intra abdominal vagal blocking medical device (Maestro® Rechargeable System): Active device will deliver vBloc Therapy.</description>
        </group>
        <group group_id="B2">
          <title>Sham (Non-active Device)</title>
          <description>The Sham group will receive a functional, but non-active device that will deliver no charge to the vagus nerve during the study period.
Active, implantable, intra abdominal vagal blocking medical device (Maestro® Rechargeable System): Control device will deliver no vBloc Therapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="162"/>
            <count group_id="B2" value="77"/>
            <count group_id="B3" value="239"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="239"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="10"/>
                    <measurement group_id="B2" value="47" spread="9"/>
                    <measurement group_id="B3" value="47" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Experiencing Implant/Revision Procedure, Device or Therapy Related Serious Adverse Events (SAEs).</title>
        <description>To demonstrate that the implant/revision procedure, device and therapy related serious adverse event rate in the vBloc group at 12 months post-implant is significantly lower than 15%.</description>
        <time_frame>12 months</time_frame>
        <population>An intent-to-treat analysis was performed in the vBloc group.</population>
        <group_list>
          <group group_id="O1">
            <title>vBloc (Active Device)</title>
            <description>The vBloc group received an active, implantable, vagal blocking medical device (Maestro® Rechargeable System) that delivered charge to the intra-abdominal anterior and posterior vagal trunks during the study period</description>
          </group>
          <group group_id="O2">
            <title>Sham (Non-active Device)</title>
            <description>The Sham group received a device that dissipated charges into an electronic circuit within the device with no lead placement. Therefore, no charge was delivered to the vagus nerve during the study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Experiencing Implant/Revision Procedure, Device or Therapy Related Serious Adverse Events (SAEs).</title>
          <description>To demonstrate that the implant/revision procedure, device and therapy related serious adverse event rate in the vBloc group at 12 months post-implant is significantly lower than 15%.</description>
          <population>An intent-to-treat analysis was performed in the vBloc group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="1.4" upper_limit="7.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Excess Weight Loss (EWL) by Body Mass Index (BMI) Method.</title>
        <description>Observe at least a 10% greater excess body weight loss (EWL) from randomization with the Maestro System after 12 months of vBloc Therapy compared to Sham by body mass index (BMI) method. (Body mass index is calculated by dividing body weight (kg) by body height (m) squared (BMI=kg/m2)).</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>vBloc (Active Device)</title>
            <description>The vBloc group will receive a functional device that will deliver charge to the vagus nerve during the study period
Active, implantable, intra abdominal vagal blocking medical device (Maestro® Rechargeable System): Active device will deliver vBloc Therapy</description>
          </group>
          <group group_id="O2">
            <title>Sham (Non-active Device)</title>
            <description>The Sham group will receive a functional, but non-active device that will deliver no charge to the vagus nerve during the study period
Active, implantable, intra abdominal vagal blocking medical device (Maestro® Rechargeable System): Control device will deliver no vBlocTherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Excess Weight Loss (EWL) by Body Mass Index (BMI) Method.</title>
          <description>Observe at least a 10% greater excess body weight loss (EWL) from randomization with the Maestro System after 12 months of vBloc Therapy compared to Sham by body mass index (BMI) method. (Body mass index is calculated by dividing body weight (kg) by body height (m) squared (BMI=kg/m2)).</description>
          <units>percentage of excess weight loss</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" lower_limit="20.8" upper_limit="28.1"/>
                    <measurement group_id="O2" value="15.9" lower_limit="11.9" upper_limit="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Responder Rate in the Treatment Arm.</title>
        <description>The second co-primary effectiveness endpoint was based on responder rates with the following two requirements: (i) at least 55% of vBloc subjects would achieve a %EWL of at least 20%; and (ii) at least 45% of vBloc subjects would achieve a %EWL of at least 25%.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>vBloc (Active Device)</title>
            <description>The vBloc group received an active, implantable, vagal blocking medical device (Maestro® Rechargeable System) that delivered charge to the intra-abdominal anterior and posterior vagal trunks during the study period</description>
          </group>
          <group group_id="O2">
            <title>Sham (Non-active Device)</title>
            <description>The Sham group received a device that dissipated charges into an electronic circuit within the device with no lead placement. Therefore, no charge was delivered to the vagus nerve during the study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Responder Rate in the Treatment Arm.</title>
          <description>The second co-primary effectiveness endpoint was based on responder rates with the following two requirements: (i) at least 55% of vBloc subjects would achieve a %EWL of at least 20%; and (ii) at least 45% of vBloc subjects would achieve a %EWL of at least 25%.</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% of subjects achieving an EWL of at least 20%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5"/>
                    <measurement group_id="O2" value="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of subjects achieving an EWL of at least 25%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3"/>
                    <measurement group_id="O2" value="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>vBloc (Active Device)</title>
          <description>The treatment group will receive a functional device that will deliver charge to the vagus nerve during the study period.
Active, implantable, intra abdominal vagal blocking medical device (Maestro® Rechargeable System): Active device will deliver vBlocTherapy.</description>
        </group>
        <group group_id="E2">
          <title>Sham (Non-active Device)</title>
          <description>The control group will receive a functional, but non-active device that will deliver no charge to the vagus nerve during the study period.
Active, implantable, intra abdominal vagal blocking medical device (Maestro® Rechargeable System): Control device will deliver no vBloc Therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Intra-operative oozing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Emesis/vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Generalized ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pain, abdominal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pain, other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladder disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Cirrhosis</sub_title>
                <description>Subject not implanted</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Worsening back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, neuroregulator site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Neuroregulator malfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Heartburn/dyspepsia</sub_title>
                <counts group_id="E1" events="46" subjects_affected="42" subjects_at_risk="162"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pain, abdominal</sub_title>
                <counts group_id="E1" events="32" subjects_affected="25" subjects_at_risk="162"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Eructation/belching</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="162"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="162"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="162"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Emesis/vomiting</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="162"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="157" subjects_affected="90" subjects_at_risk="162"/>
                <counts group_id="E2" events="62" subjects_affected="40" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pain, other</sub_title>
                <counts group_id="E1" events="136" subjects_affected="80" subjects_at_risk="162"/>
                <counts group_id="E2" events="36" subjects_affected="28" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="162"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Trauma</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="162"/>
                <counts group_id="E2" events="18" subjects_affected="11" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Reaction to medicines</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, other</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="162"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Out of range lab values</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="162"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="162"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cold/flu/respiratory tract infection</sub_title>
                <counts group_id="E1" events="121" subjects_affected="70" subjects_at_risk="162"/>
                <counts group_id="E2" events="58" subjects_affected="33" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, neuroregulator site</sub_title>
                <counts group_id="E1" events="78" subjects_affected="65" subjects_at_risk="162"/>
                <counts group_id="E2" events="37" subjects_affected="32" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Wound redness or irritation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="162"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Incision pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="162"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Research</name_or_title>
      <organization>EnteroMedics</organization>
      <phone>651-634-3209</phone>
      <email>mbroich@enteromedics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

